BRIEF — U.S. Food And Drug Administration (FDA) Approves Lilly's Onswik, A Once — Weekly Basal Insulin Injection Treatment For Adults Living With Type 2 Diabetes

Sept 24 (Reuters) — Eli Lilly and Company: U.s. Food And Drug Administration (Fda) Approves Lilly's Onswik™ (Insulin Efsitora Alfa-gobe), A Once-weekly Basal Insulin Injection Treatment For Adults Living With Type 2 Diabetes Eli Lilly - Onswik Kwikpen To Be Available In U.s. In 500 Units/ml And 1,000 Units/ml Concentrations Source text:... Further company coverage: LLY.N (Reuters.Briefs@thomsonreuters.com;)